Secretome Therapeutics Expands Rare Disease Leadership Team
Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the expansion of its leadership team with the appointments of Dr. Teji Singh, M.D., as Chief Medical Officer; David Chapman as Senior Vice President of Operations; Dr. Karin Lucas, Ph.D., as Vice President of Medical Affairs; and Maggie Loeffler, CPA, as Vice President of Finance & Administration. The Company also announced that Dr. Marshelle Smith, M.D., has transitioned into the role of Chief Development Officer.
“Secretome is evolving into a premier, rare disease-focused biopharma company, and each of the senior leaders joining our team has deep experience building world-class drug development organizations focused on rare diseases,” said Vinny Jindal, Co-Founder and Chief Executive Officer of Secretome Therapeutics. “With our leadership team in place, we are well-positioned to advance STM-01 into late-stage clinical studies for Duchenne muscular dystrophy (DMD), and to continue maturing our platform of novel regenerative therapies for a broad array of rare and underserved diseases.”
